CoChat

Predictors of clinical effectiveness of Hymenoptera venom immunotherapy

Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas‐Breit, S., Horny, H.‐P., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., Flaig, M. · 2014 · Clinical & Experimental Allergy
Cited by 139

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Background: Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors, of which the relative importance is unknown. Objective: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC), mastocytosis in the skin (MIS) and of other parameters with the frequency of objective systemic reactions during in‐hospital sting challenge (SC). Methods: In this observational retrospective study, we enrolled 1532 patients (1609 cases due to double SC) with established honeybee or vespid venom allergy who had undergone VIT and a subsequent SC. Data were collected on various putative risk factors. Adult‐onset MIS and/or a BTC > 20.0 μg/L was defined as clinical indicators of systemic mastocytosis. Relative rates were calculated with logistic regression models. Results: Ninety‐eight patients (6.4%) presented with MIS and/or BTC > 20.0 μg/L. 104 cases (6.5%) developed objective generalized symptoms during SC. In the absence of MIS, a BTC ≤ 20 μg/L did not increase the risk for VIT failure. The most important factors associated with a worse outcome were ACE inhibitor medication (OR 5.24, 95% CI 1.83–13.00, P < 0.001), honeybee venom allergy (OR 5.09, 95% CI 3.17–8.15, P < 0.001), systemic allergic reaction during VIT (OR 3.07, 95% CI 1.79–5.14, P < 0.001), and a substantial likelihood to suffer from SM (OR 2.74, 95% CI 1.37–5.22, P = 0.003), whereas a double VIT (OR 0.51, 95% CI 0.27–0.90, P = 0.027) and a longer duration of therapy (OR 0.68 per treatment month, 95% CI 0.50–0.93, P = 0.017) reduced the failure rate. Conclusion: The magnitude of therapeutic success correlates with type of venom, duration of therapy, and venom dose. Adult‐onset MIS and/or a BTC > 20 μg/L is a significant, albeit not the strongest determinant for VIT failure. According to its odds ratio, ACE inhibitor therapy appears to be associated with the highest risk for VIT failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cea.12275

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 139

Metadata

Authors
Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas‐Breit, S., Horny, H. ‐., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., & Flaig, M.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2014-04-16
Volume
44
Issue
5
Pages
736-746
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W1970297017
Cited by
139
References
7
FWCI
9.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. https://app.cochat.ai/papers/10.1111/cea.12275
The paper
Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas‐Breit, S., Horny, H. ‐., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., & Flaig, M. (2014). Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.12275

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.